Antitumor efficiencies of cytostatics dioxadet, cisplatin, mitomycin C, melphalan, and paclitaxel after a single intraperitoneal or intravenous injection in doses of 1.5, 4, 1.5, 2, and 5 mg/kg, respectively, were studied on the model of transplanted ovarian tumor in 124 rats. The antitumor effects were evaluated by the increase in median survival. Dioxadet, cisplatin, and melphalan injected intraperitoneally significantly prolonged the lifespan median – by 79, 88, and 114%, respectively, and were in fact ineffective, when injected intravenously. Intraperitoneal mitomycin C prolonged lifespan median by just 35%, intravenous – by 152%. Paclitaxel injected intraperitoneally and intravenously prolonged the lifespan median by 45 and 81%, respectively.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bespalov VG, Belyaeva OA, Kireeva GS, Senchik KYu, Stukov AN, Aristova VA, Vyshinskaya EA, Konkov SA, Krylova IA, Semenov AL, Maydin MA, Alexandrov VA, Belyaev AM. Antitumor effect of dioxadet in intraperitoneal chemoperfusion treatment for advanced ovarian cancer in experimental setting. Vopr. Onkol. 2014;60(2):72-79. Russian.
Bespalov VG, Belyaeva OA, Panchenko AV, Stukov AN, Gershanovich ML, Murazov YaG, Konkov SA, Kilmaeva NE, Krylova IM, Mironyuk TA, Latipova DKh. Antitumor activity of dioxadet compared with cisplatin activity in ascitic ovarian tumor rat model. Vopr. Onkol. 2011;57(6):771-774. Russian.
Adikesavan AK, Jaiswal AK. Thioredoxin-like domains required for glucose regulatory protein 58 mediated reductive activation of mitomycin C leading to DNA cross-linking. Mol. Cancer Ther. 2007;6(10):2719-2727.
Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield P, Grant P, Kichenadasse G, Vaughan M, Brand A, Shannon C, Gebski V, Stockler M, Friedlander M. Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. J. Gynecol. Oncol. 2013;24(4):359-366.
Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Ther. Adv. Med. Oncol. 2010;2(3):175-187.
Echarri Gonzales MJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology (Williston Park). 2011;25(2):156-165.
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5. e1257. doi: 10.1038/cddis.2013.428.
Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin. Pharmacokinet. 2012;51(4):203-224.
Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: Cancer J. Clin. 2011;61(3):183-203.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011;61(2):69-90.
Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed. Res. Int. 2015;2015. e413076. doi: 10.1155/2015/413076.
Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int. J. Womens Health. 2013;5:45-51.
Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J. Gastrointest. Oncol. 2010;2(2):109-116.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 162, No. 9, pp. 370-373, September, 2016
Rights and permissions
About this article
Cite this article
Bespalov, V.G., Vyshinskaya, E.A., Vasil’eva, I.N. et al. Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer. Bull Exp Biol Med 162, 383–386 (2017). https://doi.org/10.1007/s10517-017-3621-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-017-3621-5